293 related articles for article (PubMed ID: 29608461)
21. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
22. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
[TBL] [Abstract][Full Text] [Related]
23. Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.
Khan A; Durgam S; Tang X; Ruth A; Mathews M; Gommoll CP
Prim Care Companion CNS Disord; 2016; 18(2):. PubMed ID: 27486544
[TBL] [Abstract][Full Text] [Related]
24. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
Bauer M; Thase ME; Liu S; Earley W; Eriksson H
J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance of vilazodone treatment in patients with major depressive disorder: categorical improvement in symptoms.
Culpepper L; Mathews M; Ghori R; Edwards J
Prim Care Companion CNS Disord; 2014; 16(1):. PubMed ID: 24940525
[TBL] [Abstract][Full Text] [Related]
26. A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.
Findling RL; McCusker E; Strawn JR
J Child Adolesc Psychopharmacol; 2020 Jul; 30(6):355-365. PubMed ID: 32460523
[No Abstract] [Full Text] [Related]
27. Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials.
Thase ME; Edwards J; Durgam S; Chen C; Chang CT; Mathews M; Gommoll CP
Int Clin Psychopharmacol; 2017 Sep; 32(5):281-288. PubMed ID: 28538024
[TBL] [Abstract][Full Text] [Related]
28. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
McIntyre RS; Gommoll C; Chen C; Ruth A
CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
[TBL] [Abstract][Full Text] [Related]
30. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
[TBL] [Abstract][Full Text] [Related]
32. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
33. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
35. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Steffens DC; Nelson JC; Eudicone JM; Andersson C; Yang H; Tran QV; Forbes RA; Carlson BX; Berman RM
Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
38. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
[TBL] [Abstract][Full Text] [Related]
39. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
40. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.
Clayton AH; Gommoll C; Chen D; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Jul; 30(4):216-23. PubMed ID: 26039688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
